G1 Therapeutics Announces Addition of Norman E. Sharpless

RESEARCH TRIANGLE PARK, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...

Related Keywords

Massachusetts ,United States ,Normane Ned Sharpless ,Jack Bailey ,School Of Medicine ,National Cancer Institute ,National Institutes Of Health ,Drug Administration ,Wellcome Distinguished Professor In Cancer Research ,University Of North Carolina ,Harvard Medical School ,Nasdaq ,Exchange Commission ,Lineberger Comprehensive Cancer Center ,Therapeutics Inc ,Research Triangle Park ,Investor Relations Corporate Communications ,National Institutes ,Chief Executive Officer ,Artificial Intelligence ,Machine Learning ,Acting Commissioner ,North Carolina ,Wellcome Distinguished Professor ,Cancer Research ,Massachusetts General Hospital ,Partners Cancer Care ,Harvard Medical ,Private Securities Litigation Reform Act ,Investor Relations ,Nasdaq Gthx ,G1 Therapeutics ,